Insilico Medicine, Inc. Sustainability Profile
Insilico Medicine, Inc., a pioneering biotechnology firm headquartered in Hong Kong, is at the forefront of artificial intelligence-driven drug discovery and development. Founded in 2014, the company has rapidly established itself as a leader in the industry, leveraging advanced machine learning techniques to accelerate the drug development process. With a focus on areas such as ageing research and disease modelling, Insilico Medicine offers unique solutions that integrate AI with biology, enabling the identification of novel drug candidates and biomarkers. The company’s innovative platform has garnered significant attention, leading to partnerships with major pharmaceutical firms and academic institutions. Recognised for its contributions to the field, Insilico Medicine continues to push the boundaries of traditional drug discovery, positioning itself as a key player in the evolving landscape of biotechnology.
DitchCarbon Score
How does Insilico Medicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Insilico Medicine, Inc.'s score of 20 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Insilico Medicine, Inc.'s reported carbon emissions
Insilico Medicine, Inc., headquartered in Hong Kong, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions or reduction initiatives reported, it is unclear how Insilico Medicine, Inc. is addressing its carbon footprint or contributing to climate action within the biotechnology sector. The lack of data may suggest an opportunity for the company to develop and communicate its climate commitments more effectively in the future.
How Carbon Intensive is Insilico Medicine, Inc.'s Industry?
How Carbon Intensive is Insilico Medicine, Inc.'s Location?
Insilico Medicine, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Insilico Medicine, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
